Premium
Treatment of young adults with Philadelphia‐negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper‐CVAD vs. pediatric‐inspired regimens
Author(s) -
Siegel Stuart E.,
Advani Anjali,
Seibel Nita,
Muffly Lori,
Stock Wendy,
Luger Selina,
Shah Bijal,
DeAngelo Daniel J.,
Freyer David R.,
Douer Dan,
Johnson Rebecca H.,
HayesLattin Brandon,
Lewis Mark,
Jaboin Jerry J.,
Coccia Peter F.,
Bleyer Archie
Publication year - 2018
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25229
Subject(s) - medicine , lymphoblastic lymphoma , lymphoblastic leukemia , pediatrics , lymphoma , young adult , quality of life (healthcare) , adverse effect , oncology , leukemia , immunology , t cell , immune system , nursing
For young adults with acute lymphoblastic leukemia, pediatric‐based regimens are likely to provide the following when compared to hyper‐CVAD regimens: better disease control, less hospitalization time, diminished acute toxicities, decreased financial cost, more quality‐adjusted life years, and fewer adverse late effects, such as infertility, myelodysplasia, and second malignant neoplasms. There are also reasons to expect less cardiac and cognitive dysfunction after pediatric regimens. The improved quality and quantity of life associated with pediatric regimens renders them preferable to hyper‐CVAD regimens for the treatment of Philadelphia‐negative B‐precursor or T‐cell acute lymphoblastic leukemia and lymphoblastic lymphoma in young adults.